Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Other 3Sarcoma 1Plasma cell 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Sarcoma 1Osteosarcoma 1Chondrosarcoma 1Bone Neoplasms 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × angiotensin I (1-7) × Sarcoma × Clear all
NCT01553539 2018-07-05

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Wake Forest University Health Sciences

Phase 2 Completed
20 enrolled 10 charts
Sarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡